Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Blood

Volumn 121, Issue 11, 2013, Pages 1976-1981

  Gudbrandsdottir, Sif ^a,b   Birgens, Henrik Sverre ^c   Frederiksen, Henrik ^d   Jensen, Bjarne Anker ^c   Jensen, Morten Krogh ^c   Kjeldsen, Lars ^e   Klausen, Tobias Wirenfeldt ^c   Larsen, Herdis ^f   Mourits Andersen, Hans Torben ^g   Nielsen, Claus Henrik ^b   Nielsen, Ove Juul ^e   Plesner, Torben ^h   Pulczynski, Stanislaw ⁱ   Rasmussen, Inge Helleberg ^j   Rønnov Jessen, Dorthe ^f   Hasselbalch, Hans Carl ^a  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e Rigshospitalet   (Denmark)

^f VIBORG HOSPITAL   (Denmark)

^g Esbjerg University Hospital   (Denmark)

^h LILLEBAELT HOSPITAL   (Denmark)

ⁱ HOLSTEBRO HOSPITAL   (Denmark)

^j AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAPHYLAXIS; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BLEEDING; BONE MARROW BIOPSY; CANDIDIASIS; CATARACT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIZZINESS; ECHOGRAPHY; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTRITIS; GENITAL HERPES; HEADACHE; HUMAN; HYPERGLYCEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPLEEN SIZE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VASCULITIS; AGED; ALGORITHM; CONTROLLED CLINICAL TRIAL; MULTICENTER STUDY; ONSET AGE; PHASE 3 CLINICAL TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGE OF ONSET; AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877594229     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-455691     Document Type: Article

References (15)

1. Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):511-514.
2. Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4-13.
3. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630-1638.
4. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
5. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007; 146(1):25-33.
6. Aleem A, Alaskar AS, Algahtani F, et al. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients. Int J Hematol. 2010;92(2):283-288.
7. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results. Eur J Haematol. 2008; 81(3):165-169.
8. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14): 2755-2762.
9. Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6): 1356-1362.
10. Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98(4): 952-957.
11. Mazzucconi MG, Fazi P, Bernasconi S, et al; Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007;109(4): 1401-1407.
12. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349(9):831-836.
13. Ram R, Bonstein L, Gafter-Gvili A, et al. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon. Am J Hematol. 2009;84(4):247-250.
14. van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients [published online ahead of print November 7, 2012]. Ann Rheum Dis. 2012.
15. Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep. 2010; 12(2):94-100.